Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
93
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Development and Evaluation of Serum CST1 Detection for Early Diagnosis of Esophageal Squamous Cell Carcinoma

Jianwei Wang1 Provincial Clinical College, Fujian Medical University, Fuzhou, 350001, People’s Republic of China;2 Department of Clinical Laboratory, Fujian Provincial Hospital South Branch, Fuzhou, 350008, People’s Republic of China
,
Lili Yu1 Provincial Clinical College, Fujian Medical University, Fuzhou, 350001, People’s Republic of China;3 Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, People’s Republic of China
,
Yulong Sun4 Shanghai Liangrun Biomedicine Technology Limited Company, Shanghai, 200000, People’s Republic of China
,
Liangming Zhang1 Provincial Clinical College, Fujian Medical University, Fuzhou, 350001, People’s Republic of China;3 Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, People’s Republic of China
,
Mingshu Tu1 Provincial Clinical College, Fujian Medical University, Fuzhou, 350001, People’s Republic of China;3 Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, People’s Republic of China
,
Liqing Cai1 Provincial Clinical College, Fujian Medical University, Fuzhou, 350001, People’s Republic of China;3 Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, People’s Republic of China
,
Xiaoqing Yin3 Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, People’s Republic of China;5 Integrated Chinese and Western Medicine College, Fujian University of Traditional Chinese Medicine, Fuzhou, 350001, People’s Republic of China
,
Xiaojie Pan1 Provincial Clinical College, Fujian Medical University, Fuzhou, 350001, People’s Republic of China;6 Department of Thoracic Surgery, Fujian Provincial Hospital, Fuzhou, 350001, People’s Republic of China
,
Tao Wang4 Shanghai Liangrun Biomedicine Technology Limited Company, Shanghai, 200000, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-8531-9904
ORCID Icon &
Yi Huang1 Provincial Clinical College, Fujian Medical University, Fuzhou, 350001, People’s Republic of China;3 Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, People’s Republic of China;7 Central Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, People’s Republic of China;8 Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou, 350001, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0001-7273-8301
ORCID Icon show all
Pages 8341-8352 | Published online: 05 Nov 2021

References

  • Wang C, Wang J, Chen Z, et al. Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. Chin J Cancer. 2017;36(1):65. doi:10.1186/s40880-017-0232-528818096
  • Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–387. doi:10.1136/gutjnl-2014-30812425320104
  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
  • Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2013;381(9864):400–412. doi:10.1016/S0140-6736(12)60643-623374478
  • Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–7943. doi:10.3748/wjg.v21.i26.793326185366
  • Lagergren J, Ye W, Lagergren P, et al. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology. 2010;138(4):1297–1301. doi:10.1053/j.gastro.2010.01.00420080091
  • Kosugi S, Nishimaki T, Kanda T, et al. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg. 2004;28(7):680–685. doi:10.1007/s00268-004-6865-y15383868
  • Shimada H, Nabeya Y, Okazumi S, et al. Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg. 2003;196(4):573–578. doi:10.1016/S1072-7515(02)01905-112691934
  • Anastasi A, Brown MA, Kembhavi AA, et al. Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem J. 1983;211(1):129–138. doi:10.1042/bj21101296409085
  • Abrahamson M, Barrett AJ, Salvesen G, et al. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem. 1986;261(24):11282–11289. doi:10.1016/S0021-9258(18)67380-63488317
  • Barka T, Asbell PA, van der Noen H, et al. Cystatins in human tear fluid. Curr Eye Res. 1991;10(1):25–34. doi:10.3109/027136891090076082029847
  • Dickinson DP, Thiesse M, Dempsey LD, et al. Genomic cloning, physical mapping, and expression of human type 2 cystatin genes. Crit Rev Oral Biol Med. 1993;4(3–4):573–580. doi:10.1177/104544119300400344017690606
  • Feldman AS, Banyard J, Wu CL, et al. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009;15(3):1024–1031. doi:10.1158/1078-0432.CCR-08-114319188175
  • Breznik B, Mitrović A, Lah T, et al. Cystatins in cancer progression: more than just cathepsin inhibitors. Biochimie. 2019;166:233–250.31071357
  • Yoneda K, Iida H, Endo H, et al. Identification of Cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol. 2009;35(1):33–40.19513549
  • Choi EH, Kim JT, Kim JH, et al. Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer. Clin Chim Acta. 2009;406(1–2):45–51. doi:10.1016/j.cca.2009.05.00819463800
  • Cui Y, Sun D, Song R, et al. Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis. J Cell Physiol. 2019;234(12):22623–22634. doi:10.1002/jcp.2882831106426
  • Jiang J, Liu HL, Liu ZH, et al. Identification of cystatin SN as a novel biomarker for pancreatic cancer. Tumour Biol. 2015;36(5):3903–3910. doi:10.1007/s13277-014-3033-325577248
  • Dai DN, Li Y, Chen B, et al. Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis. J Mol Med. 2017;95(8):873–886. doi:10.1007/s00109-017-1537-128523467
  • Schwartz DR, Wu R, Kardia SL, et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res. 2003;63(11):2913–2922.12782598
  • Chen S, Liu Y, Zhang K, et al. CST1 promoted gastric cancer migration and invasion through activating Wnt pathway. Cancer Manag Res. 2021;13:1901–1907. doi:10.2147/CMAR.S27777033658852

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.